Truist raised the firm’s price target on Tenet Healthcare to $105 from $92 and keeps a Buy rating on the shares. The analyst cites the company’s strong Q4 results and normalized guidance which calls for attractive adjusted EBITDA growth. Tenet’s ASC trends remain strong, core hospital volumes are solid, and ongoing investments on several fronts including labor and high acuity service lines continue to bear fruit, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on THC: